Actarit

• Description:

  Actarit (4-Acetylaminophenylacetic acid) is an orally active Carbonic Anhydrase II (CAII) inhibitor with an IC50 of 422 nM. Actarit shows suppressive effects experimental autoimmune encephalomyelitis in rats. Actarit inhibits the development of type ll collagen (CII) -induced arthritis in mice by suppressing delayed-type hypersensitivity to CII. Actarit can be used for the study of Multiple Sclerosis (MS) and rheumatoid arthritis[1][2][3][4].

• Product Name Alternative:

  4-Acetylaminophenylacetic acid; MS-932

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Carbonic Anhydrase; IFNAR; TNF Receptor

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/actarit.html

• Concentration:

  10mM

• Purity:

  99.58

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C(C)NC(C=C1)=CC=C1CC(O)=O

• Molecular Formula:

  C10H11NO3

• Molecular Weight:

  193.20

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Kawai K, et al. Suppressive effects of 4-acetylaminophenylacetic acid (actarit) on experimental autoimmune encephalomyelitis in rats. Immunopharmacology. 1998 May;39 (2) :127-38. |[2]Fujisawa H, et al. Effect of actarit on type II collagen-induced arthritis in mice. Arzneimittel-forschung, 01 Jan 1994, 44 (1) :64-68. |[3]Ghislat G, et al. Identification and Validation of Carbonic Anhydrase II as the First Target of the Anti-Inflammatory Drug Actarit. Biomolecules. 2020 Nov 19;10 (11) :1570. |[4]Fujisawa H, et al. Suppressive effect of actarit on IgA production in mice: activation of CD4+ suppressor T-cells in Peyer's patches. Int J Immunopharmacol. 1995 Jul;17 (7) :611-7.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• CAS Number:

  [18699-02-0]